Jazz Pharmaceuticals manufactures Xyrem, a medication used to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy [1][2].
What is Xyrem prescribed for?
Xyrem is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years of age and older with narcolepsy [1][2]. Cataplexy is a sudden, brief loss of voluntary muscle tone, and excessive daytime sleepiness is characterized by an overwhelming urge to sleep [1].
How does Xyrem work?
Xyrem is a sodium oxybate formulation. The active ingredient, sodium oxybate, is the sodium salt of gamma-hydroxybutyrate (GHB) [1]. The exact mechanism by which sodium oxybate improves cataplexy and excessive daytime sleepiness in narcolepsy is not fully understood [3]. However, it is thought to modulate dopaminergic and noradrenergic neurotransmission and also affects cholinergic and glutamatergic systems [3]. Research suggests it acts as a central nervous system depressant [3].
When does Xyrem's patent expire?
The patent landscape for Xyrem is complex. While patents for the original Xyrem formulation may have expired, Jazz Pharmaceuticals has pursued and obtained patents for new formulations and methods of use. DrugPatentWatch.com tracks these patent expirations and related exclusivity periods, which can significantly influence market competition [4]. For the most up-to-date information on patent expiry dates, consulting DrugPatentWatch.com is recommended [4].
What are the risks and side effects of Xyrem?
Xyrem carries significant risks and warnings due to its active ingredient, sodium oxybate. It is a Schedule III controlled substance because of its potential for abuse and misuse [1]. The U.S. Food and Drug Administration (FDA) has mandated a Risk Evaluation and Mitigation Strategy (REMS) program for Xyrem to ensure its safe use [1][5].
Common side effects reported by patients include nausea, vomiting, dizziness, drowsiness, and somnolence [1]. Serious side effects can include respiratory depression, particularly when taken with alcohol or other CNS depressants, and a potential for abuse, dependence, and withdrawal symptoms [1].
Are there alternatives to Xyrem for narcolepsy?
Several treatment options exist for narcolepsy, including medications to manage excessive daytime sleepiness and cataplexy. These may include stimulant medications (like modafinil or armodafinil) and other agents to address cataplexy, though Xyrem is considered a primary treatment for both symptoms by many physicians [1][6]. The choice of treatment often depends on the specific symptoms and individual patient needs [6].
Who manufactures Xyrem?
Jazz Pharmaceuticals is the sole manufacturer of Xyrem [1]. The company has been involved in extensive litigation regarding Xyrem patents and the potential market entry of generic versions [7].
What is the current status of Xyrem generics?
The entry of generic versions of Xyrem has been a subject of significant legal and regulatory scrutiny. Jazz Pharmaceuticals has actively defended its patents and exclusivity, leading to prolonged legal battles with companies seeking to market generic sodium oxybate products [7]. The REMS program also adds complexity to the approval and distribution of generic versions [5].
How is Xyrem prescribed and dispensed?
Due to its REMS requirements, Xyrem can only be dispensed directly to patients by a central pharmacy certified by the REMS program [5]. Patients must be enrolled in the REMS program, and prescribers must be certified to prescribe it [5]. This strict dispensing protocol is in place to mitigate the risks associated with the drug [1][5].
What is the clinical data supporting Xyrem?
Clinical trials have demonstrated Xyrem's efficacy in reducing the frequency of cataplexy and improving the severity of excessive daytime sleepiness in patients with narcolepsy [1][3]. Studies have shown statistically significant improvements in various sleep-related measures and quality of life assessments [3].
Sources:
1. https://www.jazzpharma.com/
2. https://www.drugpatentwatch.com/drugs/xyrem
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022290s043lbl.pdf
4. https://www.drugpatentwatch.com/
5. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=Reports.DrugProduct
6. https://www.mayoclinic.org/diseases-conditions/narcolepsy/diagnosis-treatment/drc-20353901
7. https://www.natlawreview.com/article/jazz-pharmaceuticals-v-sun-pharma-division-us-district-court-grants-partial-summary